DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
AZTA logo

Azenta, Inc. Stock Price

NasdaqGS:AZTA Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AZTA Share Price Performance

US$33.63
2.57 (8.27%)
​
US$35.25
Fair Value
US$33.63
2.57 (8.27%)
4.6% undervalued intrinsic discount
US$35.25
Fair Value
Price US$33.63
AnalystConsensusTarget US$35.25
AnalystHighTarget US$37.00
AnalystLowTarget US$33.00
Thu, 3 Sep 26
Fair ValueUS$35.25
Share Pricen/a

AZTA Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$35.25 4.6% undervalued intrinsic discount

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$37 9.1% undervalued intrinsic discount

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$33 1.9% overvalued intrinsic discount

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AZTA logo
Azenta
4.6% undervalued intrinsic discount

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
AZTA logo
Azenta
9.1% undervalued intrinsic discount
Updated

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 17 Sep
Read Narrative
AZTA logo
Azenta
1.9% overvalued intrinsic discount

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 18 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
AZTA logo

AZTA: Index Additions And Leadership Transition Will Support Future Upside

Fair Value: US$37 9.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
AZTA logo

AZTA: Leadership Transition And Index Inclusion Will Shape A Measured Sentiment Recovery

Fair Value: US$35.25 4.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
AZTA logo

AZTA: Higher Guidance And Buybacks Will Offset Future P/E Compression Risks

Fair Value: US$33 1.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

0 Risks
2 Rewards
View Full Analysis

Azenta, Inc. Key Details

US$613.8m

Revenue

US$343.4m

Cost of Revenue

US$270.4m

Gross Profit

US$382.5m

Other Expenses

-US$112.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.56
44.05%
-18.26%
0%
View Full Analysis

About AZTA

Founded
1978
Employees
2900
CEO
Martin Madaus
WebsiteView website
www.azenta.com

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Recent AZTA News & Updates

User avatar
Narrative Update • Sep 03

AZTA: Leadership Transition And Index Inclusion Will Shape A Measured Sentiment Recovery

Analysts have raised their price target on Azenta stock to $35 from $28, citing updated assumptions around fair value and valuation multiples that support the higher target. What’s in the News for Azenta Azenta appointed Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta as an executive officer and director.

Recent updates

No updates

Azenta, Inc. Competitors

PRAX logo

Praxis Precision Medicines

Symbol: NasdaqGS:PRAX
Market cap: US$8.6b
IBRX logo

ImmunityBio

Symbol: NasdaqGS:IBRX
Market cap: US$8.4b
SYRE logo

Spyre Therapeutics

Symbol: NasdaqGS:SYRE
Market cap: US$8.0b
CAI logo

Caris Life Sciences

Symbol: NasdaqGS:CAI
Market cap: US$8.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide